✦ LIBER ✦

The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

✍ Scribed by Michael Eichbaum; Christine Mayer; Regina Eickhoff; Esther Bischofs; Gerhard Gebauer; Tanja Fehm; Florian Lenz; Hans-Christian Fricke; Erich Solomayer; Nikos Fersis; Marcus Schmidt; Markus Wallwiener; Andreas Schneeweiss; Christof Sohn

Book ID: 115010384
Publisher: BioMed Central
Year: 2011
Tongue: English
Weight: 191 KB
Volume: 11
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-11-453

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of trabectedin single a

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

✍ Krasner, C N; McMeekin, D S; Chan, S; Braly, P S; Renshaw, F G; Kaye, S; Provenc 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 137 KB

Topotecan and carboplatin in patients wi

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

✍ Dominique Koensgen; Dirk Stengel; Antje Belau; Peter Klare; Guelten Oskay-Oezcel 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 324 KB

Phase I clinical trial of alternating be

Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer

✍ Y. Lee; J. Hwang; H. Yoo; M. Lim; S. Seo; S. Park; S. Kang 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 80 KB

A multicenter phase II study of the cryp

A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

✍ G D’AGOSTINO; J DEL CAMPO; B MELLADO; M.A. IZQUIERDO; T MINARIK; L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

A phase 1 and pharmacodynamic study of d

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c

Treatment of recurrent platinum resistan

Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)

✍ Barbara A. Goff; Tove Thompson; Benjamin E. Greer; Andrew Jacobs; Barry Storer 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 121 KB